THLD CEO presenting tomorrow @ 8 AM to a very big crowd of healthcare investors at the Cowen Healthcare Conference in Boston. That's what is tweaking the stock upwards. Another opportunity for people to revisit the THLD story.
now that is just not right ! baby beachball has a kind heart----as long as you agree with his/her/its daily/minute assessment of everything ++++ THLD. I think his mommie maybe a security guard there
Who cares what he says ? Do you not understand what he does ? He relies on momentum charts---as many hedge people do----and hopes his contacts give him reliable information. Remember that he has to be nice or he doesn't get guest on his show. Take him with a grain of salt, especially if you are a retalil do-it-yourself person. Stick within your level of experience & understanding.
I also think he's looking (as mentioned) for the Cowen Healthcare Conference appearance next week to maybe provide THLD as a "fresh name" for those who are not in or looking for new names for their portfolios. I have been to about 25 of the conferences & they provide a great venue for small & mid cap companies to speak with major healthcare--dedicated $$$.
Cry me a river. Since when does anybody pay attention to Zacks ??? Pay attention to T Rowe Price, Fidelity, Capital Research et al. ---- WHY ARE THEY NOT SELLING ??? Any clue ? Apparently not. Maybe if d=f time allows you'll find some time & do a little research, maybe even go back & listen to a few conference calls, read some of the detailed research reports. Would hate to see you get hurt anymore.
Stifel is out today with + comments after meeting with management this week. They review the progress on the two most advanced clinical programs (pancreatic cancer & sarcoma) as well as other upcoming indications for '302. They remain + with a $12 target this year.
It's possible that Stifel is trying to get out in front of the company presentation next week at the big Cowen Healthcare Conference in Boston, which is always packed & will be again this year. Expect the company to be having private meetings with Fidelity & others to review their progress.
It won't get to those upper levels unless WFT sells their non-core assets for more or business improves so dramatically that they are just blowing earnings away. Anything is possible but wouldn't know how you arrive at such aggressive evaluations.
James Crandall---who's been covering the energy/oil service sector for 30+ years on Wall Street & has seen it all---believes WFT is setting up to be a bigs stock. He keeps 2014 EPS @ $1.10 & raises '15 estimates from $1.65 to $1.85 (assuming on core assets are sold by year end '14). This will give WFT the strongest growth in the sector among its peers, leading to a $23 stock (+40%) looking out a year. Looking out to '16 WFT is set up to be a potential $35-38 stock----handily outperforming the markets.
Look for a very positive presentation by the CEO at Cowen big Healthcare Conference in Boston. It's one of the biggest of the year & they've ben doing it for 34 years with a great turnout.
It will be $3 If the Valor results are not successful. If it is successful you have easily a $12-15 stock this year.
you must be either new to SNSS or naive. It has been expected that SNSS --- like many developmental biotech's --- would be doing an offering. So its not any surprise to the holders of the stock (maybe it is to retail holders). Also, look for a follow-on offering if they are successful on the Valor results later this summer.
This offering is already basically done. If you are playing for nickels & dimes I guess you wouldn't like it but it will be put away quickly.